P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

June 2011

Features

Drug Class Review

Protease Inhibitors for Patients With HIV-1 Infection

A Comparative Overview

Nine antiretroviral agents in the protease inhibitor class are discussed with an emphasis on their safety and efficacy.
Peter J. Hughes, PharmD; Erika Cretton-Scott, PhD; Ami Teague, PharmD, BCPS, AAHIVE; and Terri M. Wensel, PharmD, BCPS

Drug Class Review

The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection

The NNRTI class of medications has contributed significantly to the management of human immunodeficiency virus-1 (HIV-1) infection. Efavirenz (Sustiva), nevirapine (Viramune), etravirine (Intelence), and the newest FDA-approved agent, rilpivirine (Edurant), all have potential benefits when used in appropriate patients.
Jason J. Schafer, PharmD, BCPS, AAHIVE; Saranyu Ravi, PharmD Candidate; ­Evelyn V. Rowland, PharmD Candidate; Germin Shenoda, PharmD Candidate; and Nicholas Leon, PharmD, BCPS

Meeting Highlights

Digestive Disease Week 2011

Sessions cover studies of clopidogrel use in colonoscopy, rifaximin in preventing spontaneous bacterial peritonitis, the effects of teduglutide use in short-bowel syndrome and parenteral nutrition, and the link between Clostridium difficile infection and antibiotics.
Walter Alexander

Pharmaceutical Approval Update

Abiraterone (Zytiga) for advanced prostate cancer, lina­glip­tin (Tradjenta) for glycemic control, and peginterferon alfa-2b (Syl­atron) for mel­anoma
Marvin M. Goldenberg, PhD, RPh, MS

P&T Snapshot

A Survey on Managing Multiple Sclerosis

The Managed Care Perspective

In an effort to control the cost of treating patients with multiple sclerosis, many health plans have introduced restraints such as requiring prior authorization, restricting the use of the drugs to FDA-approved indications, limiting the quantity of drugs that may be prescribed, and setting dosage ­limits.
Mari Edlin and Peter Sonnenreich, MA

Departments

Medication Errors

Fluorouracil Mistake Ends With a Fatality

Applying the Lessons Learned Can Save Lives

With fluorouracil, hours can seem like days.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

New Medicare Part D Rule Affects Long-Term-Care Pharmacies

Medicare Part D: a chain of changes for long-term-care pharmacies and nursing homes
Stephen Barlas

New Drugs/Drug News/New Medical Devices

FDA approvals, drug indications, and updates

Drug Forecast

Ulipristal Acetate (ella)

A Selective Progesterone Receptor Modulator For Emergency Contraception

Ulipristal acetate (ella) for emergency contraception
Andrea Kim, PharmD Candidate; and Mary Barna Bridgeman, PharmD, BCPS